Illumina forward PE ILMN

Share price divided by analysts' consensus earnings for the next twelve months, since 2007.

Today, Oct 23, 2026: 47.2×
10-year median: 56.2×
Against its 10-year history: 32nd; percentile: 0 is its lowest day, 100 its highest
10-year range: 16.3× to 494×
Peer median: 26.4×

Illumina's forward PE is 47.2× as of Oct 23, 2026.

That is below its ten-year median of 56.2×, lower than on 68% of days in the last ten years.

Over that time it ranged from 16.3× in Apr 2025 to 494× in Dec 2022.

The median for 10 diagnostics and research stocks of a similar size is 26.4×.

Forward PE over time

median 56.2×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	47.2×	22.6×	48.7×
2025	27.7×	16.3×	33.9×
2024	33.5×	33.0×	134×
2023	129×	87.5×	490×
2022	494×	147×	494×
2021	168×	72.7×	180×
2020	71.5×	56.6×	96.3×
2019	76.9×	50.0×	76.9×
2018	54.1×	44.1×	67.8×
2017	48.4×	44.7×	53.4×
2016	41.3×	39.8×	64.3×
2015	60.2×	44.9×	74.7×
2014	62.4×	55.2×	79.8×
2013	57.7×	31.4×	57.7×
2012	36.0×	23.0×	37.6×
2011	22.1×	19.5×	61.8×
2010	51.3×	35.4×	51.6×
2009	35.1×	30.6×	50.6×
2008	35.7×	27.9×	79.4×
2007	58.4×	40.1×	74.0×

Against its peers

Companies in Medical - Diagnostics & Research nearest Illumina's size, closest first, today.

Company	Forward PE
ILMNIllumina	47.2×
IDXXIDEXX Laboratories	35.9×
WATWaters	29.2×
IQVIQVIA	20.5×
AAgilent Technologies	26.4×
MTDMettler-Toledo International	33.9×
DGXQuest Diagnostics	n/m
LHLabcorp	17.4×
MEDPMedpace	n/m
RVTYRevvity	n/m
DHRDanaher	25.4×
Peer median	26.4×

Where Illumina ranks

#49of 51Healthcare stocks with the lowest forward PE

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on Illumina

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.